Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VK 2809

Next Previous
Drug Profile

VK 2809

Alternative Names: MB-07811; VK-2809

Latest Information Update: 28 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Metabasis Therapeutics
  • Developer Duke University; Viking Therapeutics
  • Class Antihyperlipidaemics; Obesity therapies; Organophosphorus compounds; Small molecules
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypercholesterolaemia; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • No development reported Adrenoleucodystrophy; Glycogen storage disease type I

Most Recent Events

  • 10 Nov 2023 Efficacy and adverse events data from phase II VOYAGE trial in Non alcoholic steatohepatitis presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
  • 16 May 2023 Efficacy and adverse events data from phase II VOYAGE trial in Non alcoholic steatohepatitis were released by Ligand Pharmaceuticals
  • 16 May 2023 Efficacy and adverse events data from phase II VOYAGE trial in Non alcoholic steatohepatitis were released by Ligand Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top